<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940425-2-00077</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4703 -->  <!-- PJG ITAG l=11 g=1 f=1 --> Phosphono(difluromethyl)phenylalanine (F2Pmp) is a chemically and enzymatically stable mimetic of phosphotyrosine. The molecule is suitably protected for use in solid-phase peptide synthesis and could be the reagent of choice for synthesis of peptides containing stable phosphotyrosyl mimetics. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=85 g=1 f=1 --> Three Highly Informative Microsatellite DNA Markers for Use In Human Individualization <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Merril, C.R., Polymeropoulos, M.H. (NIMH) <!-- PJG 0012 frnewline --> Filed 9 Jun 93 <!-- PJG 0012 frnewline --> Serial No. 08/074,275 <!-- PJG 0012 frnewline --> Licensing Specialist: Carl C. Floyd, Ph.D. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> The present invention relates to genetic testing with polymorphic DNA markers. The repeat sequences of the markers provide a rapid and convenient high resolution process for distinguishing target nucleic acid segments on the basis of nucleotide differences according to human individualization wherein the nucleic acid segments differ in size. The invention has several applications in the areas of forensic screening, paternity and prenatal screening, as well as genetic mapping. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> The First Immortalized Kaposi's Sarcoma Cell Line <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Iskandar-Lunardi, Y.L., Gallo, R.C. (NCI) <!-- PJG 0012 frnewline --> Filed 20 Aug 93 <!-- PJG 0012 frnewline --> Serial No. 08/110,175 <!-- PJG 0012 frnewline --> Licensing Specialist: Carl C. Floyd, Ph.D. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Kaposi's Sarcoma (KS) is the most common malignancy in patients with acquired immunodeficiency syndrome (AIDS) in the U.S. The present invention makes available cell lines that provide a means for testing anti-Kaposi's Sarcoma therapies  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> in vitro, <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  or a model animal system. The invention allows therapies to be tested and dosages to be optimized prior to testing in humans. The cell line also provides a means of developing novel antitumor therapies and facilitates studies of factors that influence the development and metastasis of malignancies. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> The Cloning Of Perilipin Proteins <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=15 g=1 f=1 --> Londos, C., Greenberg, A.S., Kimmel, A.R., Egan, J.J. (NIDDK) <!-- PJG 0012 frnewline --> Filed 4 Oct 93 <!-- PJG 0012 frnewline --> Serial No. 08/132,649 <!-- PJG 0012 frnewline --> Licensing Specialist: Carl C. Floyd, Ph.D. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Perilipins are found at the surface of lipid storage droplets of adipocytes. Little is known about the molecules on the surface of lipid droplets that may be involved in lipid metabolism and trafficking. The present invention provides isolated nucleic acid sequences which encode a family of perilipin proteins as well as isolated, purified perilipin proteins. These are useful as markers for differentiation of true adipocyte cells from non-adipocyte cells which, as a result of pathophysiological conditions, assume adipocyte characteristics. <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: April 11, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Donald P. Christoferson, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Director, Office of Technology Transfer. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;9932 Filed 4&hyph;22&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4140&hyph;01&hyph;M <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            